SCOTTSDALE, Ariz. - Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company, announced the successful completion of a Phase 1 clinical trial for its drug candidate DFD-29, aimed at treating rosacea. The trial met all primary objectives and demonstrated that the drug could be safely used for up to 16 weeks without significant safety concerns or adverse effects on the microbiota of the skin, gastrointestinal tract, or vagina.
The trial, identified as DFD-29-CD-006, was a multicenter, randomized, double-blind, placebo-controlled study involving 60 healthy adults. It assessed the impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on microbial flora and evaluated the safety and tolerability of the treatment. The findings were presented at the 2024 American Academy of Dermatology Annual Meeting in San Diego, CA.
Claude Maraoui, President and CEO of Journey Medical, expressed confidence in the potential of DFD-29 to change the treatment landscape for rosacea, highlighting its ability to address both inflammatory lesions and erythema associated with the condition. The company is currently awaiting a decision on their New Drug Application for DFD-29, which is under review by the U.S. Food and Drug Administration (FDA).
Rosacea is a chronic inflammatory skin condition affecting over 16 million Americans, characterized by facial redness, acne-like lesions, and spider veins. It significantly impacts patients' self-confidence and social interactions, with severe cases affecting professional life and leading to missed workdays.
Journey Medical, founded by Fortress Biotech, Inc. (NASDAQ:FBIO), specializes in marketing FDA-approved prescription pharmaceutical products for dermatological conditions. The company is headquartered in Scottsdale, Arizona, and markets a portfolio of branded and generic skin treatment products.
The information presented in this article is based on a press release statement from Journey Medical Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.